Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR2 | O95136 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | LOX | P28300 | 1/20 | 0.33 |
| ▸ | LOXL3 | P58215 | 1/20 | 0.33 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.33 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6931382 | 0.84 | HTT (0.37) | ALDH1A1KDM4ECYP3A4CYP2C19HIF1A | |
| Hydrochloric Acid SCHEMBL15650691 | 0.82 | HTT (0.36) | ALDH1A1KDM4ECYP3A4CYP2C19HIF1A | |
| SCHEMBL27704309 | 0.79 | TDP1 (0.39) | S1PR2RECQLLOXLOXL3LOXL2 | |
| SCHEMBL31047279 | 0.79 | S1PR2 (0.32) | S1PR2RECQLLOXLOXL3LOXL2 | |
| SCHEMBL15650227 | 0.79 | NT5E (0.38) | ALDH1A1LOXLOXL2HSP90AB1KDM4E | |
| SCHEMBL31703240 | 0.79 | GRM5 (0.35) | KDM4E | |
| SCHEMBL6688414 | 0.79 | HSP90AA1 (0.36) | ALDH1A1LOXLOXL2HSP90AB1KDM4E | |
| SCHEMBL190086 | 0.77 | RECQL (0.41) | S1PR2RECQLALDH1A1LOXLOXL3 | |
| SCHEMBL6631128 | 0.76 | GRM5 (0.36) | S1PR2ALDH1A1KDM4E | |
| Hydrochloric Acid SCHEMBL6869464 | 0.74 | RECQL (0.39) | S1PR2RECQLALDH1A1LOXLOXL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260015313-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | PEPTIDREAM INC (JP) | 2026-01-15 | — | — | US | disclosed |
| EP-4655296-A1 | CBL-B INHIBITORS | Aurigene Oncology Limited (IN) | 2025-12-03 | — | — | EP | disclosed |
| EP-4534524-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | PeptiDream Inc. (JP) | 2025-04-09 | — | — | EP | disclosed |
| WO-2024193689-A1 | PYRIDINOPYRROLE DERIVATIVE AND USE THEREOF IN DRUGS | 广东东阳光药业股份有限公司 | 2024-09-26 | — | — | WO | disclosed |
| CN-118684665-A | Pyridopyrrole derivatives and their use in medicine | 广东东阳光药业股份有限公司 | 2024-09-24 | — | — | CN | disclosed |
| WO-2024156938-A1 | CBL-B INHIBITORS | ORION CORPORATION (FI) | 2024-08-02 | — | — | WO | disclosed |
| WO-2023234425-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | ペプチドリーム株式会社 | 2023-12-07 | — | — | WO | disclosed |
| US-20170355708-A1 | POTASSIUM CHANNEL MODULATORS | CADENT THERAPEUTICS, INC. | 2017-12-14 | — | — | US | disclosed |
| US-20170355708-A1 | POTASSIUM CHANNEL MODULATORS | CADENT THERAPEUTICS, INC. | 2017-12-14 | — | — | US | disclosed |
| US-20170355708-A1 | POTASSIUM CHANNEL MODULATORS | CADENT THERAPEUTICS, INC. | 2017-12-14 | — | — | US | disclosed |
| EP-1054877-A1 | NOVEL CYCLIC SULFONAMIDE DERIVATIVES AS METALLOPROTEINASE INHIBITORS | Du Pont Pharmaceuticals Company (US) | 2000-11-29 | — | — | EP | disclosed |
| EP-1027332-A1 | NOVEL LACTAM METALLOPROTEASE INHIBITORS | Du Pont Pharmaceuticals Company (US) | 2000-08-16 | — | — | EP | disclosed |
| US-6057336-A | ANTIINFLAMMATORY AGENTS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2000-05-02 | — | — | US | disclosed |
| WO-1999065867-A1 | CYCLIC HYDROXAMIC ACIDS AS METALLOPROTEINASE INHIBITORS | DU PONT PHARMACEUTICALS COMPANY (US) | 1999-12-23 | — | — | WO | disclosed |
| WO-1999041246-A1 | NOVEL CYCLIC SULFONAMIDE DERIVATIVES AS METALLOPROTEINASE INHIBITORS | DU PONT PHARMACEUTICALS COMPANY (US) | 1999-08-19 | — | — | WO | disclosed |
| WO-1999018074-A1 | NOVEL LACTAM METALLOPROTEASE INHIBITORS | Britol-Myers Squibb Pharma Company (US) | 1999-04-15 | — | — | WO | disclosed |
| US-5877190-A | PHOSPHODIESTERASE INHIBITOR | ADIR ET COMPAGNIE (FR) | 1999-03-02 | — | — | US | disclosed |
| US-5254679-A | Containing a quaternized nitrogen | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-10-19 | — | — | US | disclosed |
| EP-0164944-B1 | CEPHALOSPORIN DERIVATIVES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-07-11 | — | — | EP | disclosed |
| EP-0164944-A1 | Cephalosporin derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1985-12-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260015313-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | NSUN3, BCAT1, SLC43A1 | S1PR2 4330/4885RECQL 2737/4885TRPA1 4639/4885 |
| US-20170355708-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ11, KCNJ2, KCNJ1 | S1PR2 975/4885RECQL 1737/4885TRPA1 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.